Patents by Inventor Howland Shaw Warren
Howland Shaw Warren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230158182Abstract: Described herein are methods and devices for selectively diminishing viability of or killing bacterial, fungal, or viral pathogens using acoustic excitation below the thresholds for cavitation.Type: ApplicationFiled: November 17, 2022Publication date: May 25, 2023Inventors: Peter Donald Haaland, Howland Shaw Warren
-
Publication number: 20220062379Abstract: The invention relates to a method for treating a disease of immune dysregulation or altering an immune response or both in a mammal Such methods include administering to the mammal a therapeutically effective amount of a modulating agent or subjecting the mammal to a modulating process, wherein the modulating agent or process alters the expression or activity of a gene target associated with a sensitive response or a resistant response to an inflammatory stimulus.Type: ApplicationFiled: January 17, 2020Publication date: March 3, 2022Inventors: Howland Shaw WARREN, David GREGORY, Wenzhong XIAO, Feifei HAN, Luis BARREIRO, Judith HELLMAN
-
Publication number: 20210251848Abstract: Devices, systems and methods for stimulating (e.g., noninvasively) a subject's inflammatory reflex are provided to reduce bleed time. The method may include the step of non-invasively stimulating the inflammatory reflex (e.g., the vagus nerve, the splenic nerve, the hepatic nerve, the facial nerve, and the trigeminal nerve) of a subject, such as by mechanical stimulation, in a manner which significantly reduces bleed time in the subject. Devices for non-invasively stimulating the inflammatory reflex may include a movable tip or actuator that is controlled to mechanically stimulate the ear. The devices may be hand-held or wearable, and may stimulate the cymba conchae region of the subject's ear.Type: ApplicationFiled: February 8, 2021Publication date: August 19, 2021Inventors: Kevin J. TRACEY, Howland Shaw WARREN, Michael Allen FALTYS, Carol Ann AMELLA, Christopher CZURA, Jared M. HUSTON
-
Patent number: 10912712Abstract: Devices, systems and methods for stimulating (e.g., noninvasively) a subject's inflammatory reflex are provided to reduce bleed time. The method may include the step of non-invasively stimulating the inflammatory reflex (e.g., the vagus nerve, the splenic nerve, the hepatic nerve, the facial nerve, and the trigeminal nerve) of a subject, such as by mechanical stimulation, in a manner which significantly reduces bleed time in the subject. Devices for non-invasively stimulating the inflammatory reflex may include a movable tip or actuator that is controlled to mechanically stimulate the ear. The devices may be hand-held or wearable, and may stimulate the cymba conchae region of the subject's ear.Type: GrantFiled: September 26, 2017Date of Patent: February 9, 2021Assignee: The Feinstein Institutes for Medical ResearchInventors: Kevin J. Tracey, Howland Shaw Warren, Michael Allen Faltys, Carol Ann Amella, Christopher Czura, Jared M. Huston
-
Publication number: 20180021217Abstract: Devices, systems and methods for stimulating (e.g., noninvasively) a subject's inflammatory reflex are provided to reduce bleed time. The method may include the step of non-invasively stimulating the inflammatory reflex (e.g., the vagus nerve, the splenic nerve, the hepatic nerve, the facial nerve, and the trigeminal nerve) of a subject, such as by mechanical stimulation, in a manner which significantly reduces bleed time in the subject. Devices for non-invasively stimulating the inflammatory reflex may include a movable tip or actuator that is controlled to mechanically stimulate the ear. The devices may be hand-held or wearable, and may stimulate the cymba conchae region of the subject's ear.Type: ApplicationFiled: September 26, 2017Publication date: January 25, 2018Inventors: Kevin J. TRACEY, Howland Shaw WARREN, Michael Allen FALTYS, Carol Ann AMELLA, Christopher CZURA
-
Publication number: 20160250097Abstract: Described herein are devices, systems and method for treating inflammatory disorders by modulating a subject's inflammatory reflex. The method may include the step of non-invasively stimulating the inflammatory reflex (e.g., the vagus nerve, the splenic nerve, the hepatic nerve, the facial nerve, and the trigeminal nerve) of a subject in a manner which significantly reduces proinflammatory cytokines in the subject and/or provides a therapeutically effective treatment for the subject. Devices for non-invasively stimulating the inflammatory reflex may include a movable tip or actuator that is controlled to mechanically stimulate the ear. The devices may be hand-held or wearable, and may stimulate the cymba conchae region of the subject's ear.Type: ApplicationFiled: March 13, 2008Publication date: September 1, 2016Applicant: The Feinstein Institute for Medical ResearchInventors: Kevin J. Tracey, Howland Shaw Warren, Michael Allen Faltys
-
Patent number: 8501173Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise a vertebrate HMGB A box, and an antibody preparation that specifically binds to a vertebrate HMGB B box. The methods comprise treating a cell or a patient with sufficient amounts of the composition to inhibit the release of the proinflammatory cytokine, or to inhibit the inflammatory cytokine cascade.Type: GrantFiled: January 11, 2011Date of Patent: August 6, 2013Assignees: The General Hospital Corporation, The Feinstein Institute for Medical Research, University of Pittsburgh—of the Commonwealth System of Higher EducationInventors: Kevin J. Tracey, Huan Yang, Howland Shaw Warren, Jr., Mitchell P. Fink
-
Patent number: 8391970Abstract: Described herein are methods, devices and systems for inhibition of granulocyte activation by appropriate stimulation of the vagus nerve. Methods of treating granulocyte-mediated disorders (including inflammatory disorders) by stimulating the vagus nerve to inhibit granulocyte activation (particularly neutrophil activation) are also described. Appropriate stimulation may be very low levels of stimulation, including stimulation that does not result in desensitization. The level of granulocyte activation may be detected and used to at least partially control stimulation.Type: GrantFiled: August 26, 2008Date of Patent: March 5, 2013Assignee: The Feinstein Institute for Medical ResearchInventors: Kevin J. Tracey, Howland Shaw Warren, Christine N. Metz
-
Publication number: 20110268695Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise a vertebrate HMGB A box, and an antibody preparation that specifically binds to a vertebrate HMGB B box. The methods comprise treating a cell or a patient with sufficient amounts of the composition to inhibit the release of the proinflammatory cytokine, or to inhibit the inflammatory cytokine cascade.Type: ApplicationFiled: January 11, 2011Publication date: November 3, 2011Applicants: The Feinstein Institute for Medical Research, University of Pittsburgh of the Commonwealth System of Higher Education, The General Hospital CorporationInventors: Kevin J. Tracey, Huan Yang, Howland Shaw Warren, JR., Mitchell P. Fink
-
Patent number: 7897569Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise a vertebrate HMGB A box, and an antibody preparation that specifically binds to a vertebrate HMGB B box. The methods comprise treating a cell or a patient with sufficient amounts of the composition to inhibit the release of the proinflammatory cytokine, or to inhibit the inflammatory cytokine cascade.Type: GrantFiled: September 19, 2007Date of Patent: March 1, 2011Assignees: The Feinstein Institute for Medical Research, The General Hospital Corporation, University of Pittsburgh of the Commonwealth System of Higher EducationInventors: Kevin J. Tracey, Huan Yang, Howland Shaw Warren, Jr., Mitchell P. Fink
-
Patent number: 7749959Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise a vertebrate HMGB A box, and an antibody preparation that specifically binds to a vertebrate HMGB B box. The methods comprise treating a cell or a patient with sufficient amounts of the composition to inhibit the release of the proinflammatory cytokine, or to inhibit the inflammatory cytokine cascade.Type: GrantFiled: September 19, 2007Date of Patent: July 6, 2010Assignees: The Feinstein Institute for Medical Research, The General Hospital Corporation, University of Pittsburgh-of the Commonwealth System of Higher EducationInventors: Kevin J. Tracey, Huan Yang, Howland Shaw Warren, Jr., Mitchell P. Fink
-
Publication number: 20090062874Abstract: Described herein are methods, devices and systems for inhibition of granulocyte activation by appropriate stimulation of the vagus nerve. Methods of treating granulocyte-mediated disorders (including inflammatory disorders) by stimulating the vagus nerve to inhibit granulocyte activation (particularly neutrophil activation) are also described. Appropriate stimulation may be very low levels of stimulation, including stimulation that does not result in desensitization. The level of granulocyte activation may be detected and used to at least partially control stimulation.Type: ApplicationFiled: August 26, 2008Publication date: March 5, 2009Inventors: Kevin J. Tracey, Howland Shaw Warren, Christine N. Metz
-
Publication number: 20080249439Abstract: Described herein are devices, systems and method for treating inflammatory disorders by modulating a subject's inflammatory reflex. The method may include the step of non-invasively stimulating the inflammatory reflex (e.g., the vagus nerve, the splenic nerve, the hepatic nerve, the facial nerve, and the trigeminal nerve) of a subject in a manner which significantly reduces proinflammatory cytokines in the subject and/or provides a therapeutically effective treatment for the subject. Devices for non-invasively stimulating the inflammatory reflex may include a movable tip or actuator that is controlled to mechanically stimulate the ear. The devices may be hand-held or wearable, and may stimulate the cymba conchae region of the subject's ear.Type: ApplicationFiled: March 13, 2008Publication date: October 9, 2008Applicant: The Feinstein Institute for Medical ResearchInventors: Kevin J. Tracey, Howland Shaw Warren, Michael Allen Faltys
-
Publication number: 20080214454Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise a vertebrate HMGB A box, and an antibody preparation that specifically binds to a vertebrate HMGB B box. The methods comprise treating a cell or a patient with sufficient amounts of the composition to inhibit the release of the proinflammatory cytokine, or to inhibit the inflammatory cytokine cascade.Type: ApplicationFiled: September 19, 2007Publication date: September 4, 2008Inventors: Kevin J. Tracey, Huan Yang, Howland Shaw Warren, Mitchell P. Fink
-
Publication number: 20080167234Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise a vertebrate HMGB A box, and an antibody preparation that specifically binds to a vertebrate HMGB B box. The methods comprise treating a cell or a patient with sufficient amounts of the composition to inhibit the release of the proinflammatory cytokine, or to inhibit the inflammatory cytokine cascade.Type: ApplicationFiled: September 19, 2007Publication date: July 10, 2008Inventors: Kevin J. Tracey, Huan Yang, Howland Shaw Warren, Mitchell P. Fink
-
Patent number: 7304034Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise a vertebrate HMGB A box, and an antibody preparation that specifically binds to a vertebrate HMGB B box. The methods comprise treating a cell or a patient with sufficient amounts of the composition to inhibit the release of the proinflammatory cytokine, or to inhibit the inflammatory cytokine cascade.Type: GrantFiled: November 20, 2002Date of Patent: December 4, 2007Assignees: The Feinstein Institute for Medical Research, The General Hospital Corporation, University of Pittsburgh-Of the Commonwealth System of Higher EducationInventors: Kevin J. Tracey, Huan Yang, Howland Shaw Warren, Jr., Mitchell P. Fink
-
Publication number: 20040068006Abstract: Disclosed is a method of treating acute renal failure in a subject. The method comprises the step of administering to the subject an effective amount of a composition comprising a 2-ketoalkanoic acid, a pharmaceutically acceptable salt of a 2-ketoalkanoic acid, an ester of a 2-ketoalkanoic acid, or an amide of a 2-ketoalkanoic acid. Preferably, the composition comprises an enolization agent and an alkyl aralkyl, alkoxyalkyl or carboxyalkyl ester of a 2-ketoalkanoic acid dissolved in a pharmaceutically acceptable vehicle.Type: ApplicationFiled: October 3, 2003Publication date: April 8, 2004Applicant: Critical Therapeutics, Inc.Inventors: Mitchell P. Fink, Howland Shaw Warren
-
Publication number: 20030144201Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise a vertebrate HMGB A box, and an antibody preparation that specifically binds to a vertebrate HMGB B box. The methods comprise treating a cell or a patient with sufficient amounts of the composition to inhibit the release of the proinflammatory cytokine, or to inhibit the inflammatory cytokine cascade.Type: ApplicationFiled: November 20, 2002Publication date: July 31, 2003Applicant: North Shore-Long Island Jewish Research InstituteInventors: Kevin J. Tracey, Huan Yang, Howland Shaw Warren, Mitchell P. Fink
-
Publication number: 20030060410Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise a vertebrate HMG A box, and an antibody preparation that specifically binds to a vertebrate HMG B box. The methods comprise treating a cell or a patient with sufficient amounts of the composition to inhibit the release of the proinflammatory cytokine, or to inhibit the inflammatory cytokine cascade.Type: ApplicationFiled: May 15, 2002Publication date: March 27, 2003Applicant: North Shore Long Island Jewish Research InstituteInventors: Kevin J. Tracey, Huan Yang, Howland Shaw Warren, Mitchell P. Fink